Microbes exert a major impact on human health and disease by either promoting or disrupting homeostasis, in the latter instance leading to the development of infectious diseases. Such disparate outcomes are driven by the ever-evolving genetic diversity of microbes and the countervailing host responses that minimize their pathogenic impact. Host defense strategies that limit microbial pathogenicity include resistance mechanisms that exert a negative impact on microbes, and disease tolerance mechanisms that sustain host homeostasis without interfering directly with microbes. While genetically distinct, these host defense strategies are functionally integrated, via mechanisms that remain incompletely defined. Here, we explore the general principles via which host adaptive responses regulating iron (Fe) metabolism impact on resistance and disease tolerance to infection.
Introduction
The pathogenic outcome of host-microbe interactions is countered by a number of evolutionarily conserved host defense strategies [1] . These include avoidance, a behavioral-based strategy that limits exposure of the host to potentially pathogenic microbes [2] . Physical barriers in the form of different epithelia provide an additional defense strategy that prevents microbes from gaining systemic host access [3] . In the event of an infection, when microbes become systemic, immune-driven resistance mechanisms exert a negative impact on microbes that limits their pathogenicity. Resistance to infection relies, in most cases, on the expression of cytotoxic molecules that target pathogens. However, there are also resistance mechanisms that rely on the expression of molecules that while not cytotoxic per se prevent pathogens from accessing metabolites and/ or nutrients that are essential for their survival and/or proliferation. This defense strategy, termed nutritional immunity [4] , encompasses mechanisms that restrict microbes from accessing iron (Fe) [5] [6] [7] as well as other trace metals such as zinc, manganese, or copper [8, 9] . That nutritional immunity is a central defense strategy against infection is supported by the realization that several "infection resistance genes" act via a mechanism controlling host Fe metabolism.
While essential to confer host protection against infection, some resistance mechanisms, including those involved in nutritional immunity, can compromise host homeostasis [10] . This trade-off is countered by an additional host defense strategy termed as tissue damage control [1, 11] , which confers disease tolerance to infection [1, 12, 13] . The term disease tolerance, as used herein, refers to the same phenomenon identified originally in host-microbe interactions in plants [14] . It limits the impact of infection on host integrity and fitness without interfering with the host's pathogen burden [14] . This is distinct from immunological tolerance [15] , and while the two may be functionally linked, they act via distinct mechanisms.
Here, we explore how adaptive responses regulating host Fe metabolism impact on resistance and disease tolerance to infection. We will put forward the notion that pathogen class-specific mechanisms regulating Fe metabolism evolved to confer protection against intracellular versus extracellular pathogens. Other recent reviews focusing on related aspects of Fe metabolism, in the context of infection, are cited throughout the manuscript [6, 7, [16] [17] [18] .
Regulation of Fe metabolism during infection
Host-microbe interactions evolved in a manner that is often linked to the emergence of host adaptive responses that regulate Fe metabolism and impact on Fe availability for microbes [5] . These adaptive responses carry a trade-off such that modulation of Fe metabolism can only occur within narrow limits, compatible with host homeostasis [10] . The general principle being that adaptive responses supplying Fe to microbes increase, in most cases, their pathogenicity while those withholding Fe from microbes limit their virulence. In support of this notion, host Fe overload is associated with poor clinical outcomes in a number of infectious diseases such as AIDS (i.e., co-infections resulting from HIV-driven immunodeficiency), malaria, and tuberculosis [19] [20] [21] [22] , while dietary Fe supplementation exacerbates the overall rate of mortality in areas endemic for such infectious diseases [23] [24] [25] [26] [27] . Of note, systemic Fe chelation yields inconsistent clinical outcomes, as illustrated for malaria or invasive fungal infections [20, 28] , reflecting the complex interplay between host Fe metabolism and the pathogenesis of infectious diseases.
Microbes evolved strategies to acquire Fe from their hosts [5] [6] [7] 17] . These share as a common denominator the expression of siderophores that elute Fe from host Fe-binding proteins [29, 30] as well as other Fe uptake systems [6, 31] . Of note, deletion of genes regulating the expression of siderophores or other Fe uptake systems is often associated with reduced pathogen virulence, as illustrated for bacteria, for example, Staphylococci and Salmonella, or fungi, for example, Aspergillus, infections [6, 7, 32, 33] . Along this line, polymorphisms in host genes encoding Fe-binding proteins that counter microbial siderophores or other microbial Fe uptake systems enhance resistance to bacterial infections [34] .
The majority of bioavailable Fe in mammals exists in the form of heme (Fig 1) . It is therefore reasonable to assume that microbes evolved strategies to extract Fe from this tetrapyrrole ring structure [7, 30] . Examples are provided by Gram-positive bacteria such as Staphylococcus aureus, which expresses a specific hemoglobin receptor (IsdB), promoting heme extraction from hemoglobin [35] . This is also the case for Gram-negative bacteria, such as Escherichia (E.) coli that express evolutionary conserved heme receptors, which bind and promote heme degradation [36] . The same may hold true for protozoan parasites such as Plasmodium, which can incorporate host heme into their own metabolic pathways [37] .
Host heme metabolism is controlled by several genes [38] , including some that might restrict Fe access to microbes. This is probably the case for haptoglobin (HP) and hemopexin (HPX), two acute-phase proteins that scavenge extracellular hemoglobin and labile heme in plasma, respectively [39] . Moreover, heme catabolism by heme oxygenase-1 (HO-1), a stress-responsive enzyme that converts labile heme into equimolar amounts of Fe, carbon monoxide (CO), and biliverdin [40] , should also contribute to deprive microbes from accessing Fe contained in heme. That these genes modulate the pathogenesis of infectious diseases in humans is supported by the association of polymorphisms in the human HP genes with an unfavorable course of co-infections resulting from HIV-driven immunodeficiency [41] , malaria [42] , or tuberculosis [43] . This also holds true for polymorphisms in the human HMOX1 gene coding for HO-1, as illustrated for HIV infection [44] and malaria [45, 46] . More recently, an association between plasma levels of HO-1 and active versus latent or treated pulmonary tuberculosis has been established [47] . This suggests that host adaptive responses regulating heme metabolism and depriving microbes from accessing this source of Fe can exert a major impact on the outcome of infectious diseases. (Fig 1) . Hemophagocytic Mø engulf senescent and damaged erythrocytes, digest their hemoglobin content in phagolysosomes, and extract the prosthetic heme groups from hemoglobin (Fig 1) . Labile heme is transferred to the cytoplasm via a mechanism assisted by the heme transporter heme-responsive gene-1 (HRG1) [50, 51] (Fig 1, top right More than 80% of the bioavailable Fe in mammals exists in the form of heme contained in hemoproteins [241] . The most abundant pool of Fe in mammals are the prosthetic heme groups of hemoglobin in red blood cells (RBC), followed by the heme groups of myoglobin in muscle cells and those of cytochromes and other ubiquitously expressed hemoproteins in all cells [38, 54] . The Fe required to sustain hemoglobin synthesis is made available by hemophagocytic Mø as these clear senescent RBC by erythrophagocytosis (top right) [49] . The heme contained in hemoglobin is transported by heme-responsive gene-1 (HRG1) into the cytoplasm where Fe is extracted by hemeoxygnease-1 (HO-1), exported via ferroportin (FPN), and delivered to traferrin (Tf) in plasma. Surplus cytoplasmic Fe in Mø is incorporated and stored within ferritin. Tf transports and provides Fe to the erythropoietic compartment via TfR, where it is used for heme synthesis (bottom right). Heme synthesis occurs via eight successive enzymatic reactions that take place back and forward in the mitochondria (brown) and the cytosol (blue). For details, see Box 1. 
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Pathogen class-specific regulation of Fe metabolism
Pathogen class-specific mechanisms evolved most probably to limit Fe availability to extracellular versus intracellular pathogens, while Heme synthesis occurs via eight successive enzymatic reactions that take place back and forward in the mitochondria and the cytosol. The first consists in the condensation of glycine and succinyl-CoA into d-aminolevulinic acid (ALA), catalyzed by the mitochondrial d-aminolevulinate synthase (ALAS1/2). ALA translocates to the cytosol where it reacts with pyridoxal phosphate to form a porphobilinogen, via a reaction catalyzed by porphobilinogen synthase (PBGS). The resulting four porphobilinogen molecules are condensed by hydroxylmethylbilane synthase (HMBS) to generate hydroxymethylbilane, which is converted to uroporphyrinogen I and then to coproporphyrinogen I by a non-enzymatic and an enzymatic reaction catalyzed by uroporphyrinogen III co-synthase or isomerase (UROS). Decarboxylation of uroporphyrinogen III forms coproporphyrinogen III, via a reaction catalyzed by uroporphyrinogen III decarboxylase (UROD). Coproporphyrinogen III is then transported to the mitochondria where coproporphyrinogen oxidase (CPOX) catalyzes its oxidative decarboxylation into protoporphyrinogen IX, subsequently oxidized to protoporphyrin IX (PPIX) by protoporphyrin oxidase (PPOX). The final step consists in the insertion of the Fe, originating from hemophagocytic Mø and provided via transferrin, into newly synthesized protoporphyrinogen IX, via an enzymatic reaction catalyzed by ferrochelatase (FECH) [242] . See also Fig 1. enhancing resistance mechanisms [17, 94, 95] . Induction of hypoferremia, via systemic inhibition of extracellular Fe export coupled to increased Mø Fe/heme uptake and intracellular retention [5, 6] 
Regulation of Fe metabolism as a host resistance mechanism against extracellular pathogens
The general strategy to restrict Fe access to extracellular pathogens consists in the retention of intracellular Fe by Mø leading to hypoferremia (Fig 2) . This is achieved essentially by the induction of Fe import and retention mechanisms, coupled to suppression of cellular Fe export (Fig 2) . Activated Mø can produce minute amounts of hepcidin in response to bacterial lipopolysaccharide (LPS) or cytokines, targeting FPN for proteolytic degradation [109, 110] . However, while this may provide a fast acting strategy to limit Mø Fe export, sustained Fe retention requires additional inputs provided by cytokines such as IFNc, which represses FPN transcription [6] (Fig 2) . IFNc also induces the expression of iNOS/NOS2 [78], via a mechanism regulated at a transcriptional level by the activation of the signal transducers and activators of transcription (STAT) family of transcription factors (Fig 2) . As described above, the NO produced by iNOS/NOS2 regulates the binding affinities of IRP toward target IRE in genes such as transferrin receptor (TfR) and ferritin, inhibiting cellular Fe import and intracellular retention, respectively [58,81,82,111]. However, once intracellular Fe levels increase in Mø, iNOS/NOS2 transcription is repressed creating a negative feedback loop, which promotes intracellular Fe retention [85, 111] . IFNc also induces the expression of the divalent metal transporter-1 (DMT1) in Mø, promoting ferrous Fe uptake and intracellular incorporation by ferritin [112] (Fig 2) . Cytokine-driven NF-jB activation induces FTH transcription, supporting further retention of Fe in Mø [54, 55] (Fig 2) .
Other cytokines such as IL-4, IL-10, and IL-13 promote TfRmediated Fe uptake and intracellular retention by ferritin [113] . Moreover, IL-10 and IL-6 also increase heme uptake from circulating hemoglobin-haptoglobin or heme-HPX complexes, via a mechanism involving the induction of the hemoglobin scavenger receptor CD163 and the HPX scavenger receptor CD91 [114, 115] , respectively (Fig 2) . This is coupled to the induction of HO-1 in Mø [116] , which extracts Fe from heme and promotes intracellular Fe storage by ferritin (Fig 2) .
Another resistance mechanism against extracellular pathogens, based on regulation of Fe metabolism, involves the expression of lactoferrin, a member of the transferrin family of Fe-binding proteins (Fig 2) . Lactoferrin is expressed in many tissues and secretions where its primary function is to bind and restrict Fe delivery to extracellular microbes, a mechanism which accounts for its antimicrobial activity in breast milk [117] . Activated Mø express and release lactoferrin, which scavenges and restricts Fe availability to extracellular pathogens [6, 117, 118] (Fig 2) . Lactoferrin also protects Mø from oxidative stress [117,119] and modulates Mø microbicidal activity, as shown in the context of Staphylococcus aureus infection [120, 121] . The Fe-binding capacity of lactoferrin can also interfere with microbial virulence pathways such as biofilm formation [122] . Moreover, lactoferrin modulates the activation and proliferation of lymphocytes, NK cells, and Mø, via a mechanism mediated in part by lactoferrin receptors expressed by these cells [117, 123] . Cellular internalization of Fe-loaded lactoferrin by Mø can lead to cellular Fe overload and cytotoxicity [124] . Of note, some bacteria evolved strategies to subvert the protective effects of lactoferrin extracting Fe from lactoferrin [125, 126] . Although the exact mechanism by which bacteria can extract iron from lactoferrin remains to be determined, some Gram-negative bacteria can import lactoferrin following its binding to microbial transmembrane lactoferrin binding proteins A and B [127, 128] .
Lipocalin (Lcn2/NGAL) is a peptide produced by activated polymorphonuclear (PMN) cells and Mø, which captures Fe-laden bacterial catechole type siderophores, such as enterobactin, derived from Gram-negative bacteria (Fig 2) . Lcn2 inhibits the acquisition of siderophore-bound Fe by bacteria, as illustrated for E. coli or Klebsiella spp. Taken together, these observations argue that several mechanisms evolved to regulate host Fe metabolism in a manner that limits the proliferation capacity and virulence of extracellular pathogens. Moreover, leakage of hemoglobin from red blood cells appears to be an ancestral and evolutionary conserved defense strategy that targets extracellular pathogens for heme-driven oxidative cytotoxicity. This defense mechanism was also retained in arthropods, in which the hemoglobin functional homolog hemocyanin displays similar antimicrobial functions [138] . Regulation of Fe metabolism as a host resistance mechanism against intracellular pathogens There is at least one additional mechanism by which NRAMP1 confers resistance to intracellular bacteria such as Salmonella, namely via the induction of Lcn2 expression [156] . Of note, Lcn2 can control the proliferation of intracellular bacteria that do not produce siderophores, such as Chlamydia pneumonia [157] (Fig 3) (Fig 3) . Of note, impaired resistance to Salmonella infection in iNos/Nos2-deficient mice can be restored by pharmacologic Fe chelation, arguing that the microbicidal effect of NO acts, at least partly, via regulation of intracellular Fe content [73] . A similar resistance mechanism may be of importance for other infectious diseases, such as trypanosomiasis [161] .
When expressed in phagosomes FPN can reduce Fe supply to pathogens in this subcellular compartment, as shown in vitro for Mycobacteria infection [101] (Fig 3) . The pathophysiologic relevance of this mechanism is illustrated by the fact that individuals carrying mutations in the FPN gene, which is associated with intracellular Fe retention and secondary siderosis in Africa (also termed Bantu disease), are challenged with an increased incidence of Mycobacteria infection and higher mortality from tuberculosis [162] . Of interest, some intracellular bacteria can counterbalance this host response, as illustrated for Salmonella spp., which promotes the expression of hepcidin in the liver via the induction of estrogen receptor gamma-mediated cascade. Subsequent degradation of FPN favors intracellular Fe accumulation, thereby promoting pathogen growth [163] .
Intracellular Fe accumulation in Mø represses IFNc receptor signaling, most likely explaining why reducing intracellular Fe content promotes IFNc-driven resistance pathways involving the induction of histocompatibility (MHC) class II, iNOS/NOS2 TNF, IL-6, or IL-12 expression [164-167]. The mechanisms underlying this effect have not been entirely elucidated, but involve the transcription factors hypoxia-inducible factor 1a (HIF1a) nuclear factor for IL-6 expression (NF-IL6) and STAT and likewise phosphokinase-controlled pathways [164] [165] [166] [167] . This suggests that mechanisms reducing intracellular Fe availability in Mø have a dual role, limiting microbial access to intracellular Fe while boosting antimicrobial resistance mechanisms in response to cytokines such as IFNc [6] . This is in line with the recent observation that IRP expression and their subsequent regulatory effects on cellular Fe homeostasis in Mø confer resistance to Salmonella infection by restricting Fe availability to the bacterium and by promoting antimicrobial immune effector mechanisms of Mø [168] . Finally, signaling via the IFNc receptor also induces FPN expression while inhibiting extracellular Fe uptake via the transferrin receptor [169] and inducing Lcn2 expression [135] in Mø (Fig 3) .
Heme catabolism by HO-1 also supports resistance to intracellular bacteria, as suggested for Mycobacteria infection in mice [170, 171] . While it is not clear whether this effect is mediated via CO and/or other products of heme catabolism, such as biliverdin and Fe, it is likely that the cytoprotective effect of CO [172] prevents infected Mø from undergoing programmed cell death by necroptosis [173] . This cytoprotective effect should support granuloma formation and hence resistance to Mycobacteria [170, 171] . The recent finding that Mø necroptosis impairs granuloma formation and compromises resistance to Mycobacteria infection in zebrafish supports this notion [174] . Whether this cytoprotective effect is of importance for host resistance to other intracellular pathogens that evolved mechanisms to subvert Mø programmed cell death, such as Listeria, Salmonella, or Shigella spp., remains to be established.
It appears that several mechanisms evolved to reduce the intracellular Fe content of Mø infected by intracellular pathogens. This achieves several goals, namely to limit Fe access to intracellular pathogens while modulating Mø polarization and maintaining Mø viability, all of which concur to limit the virulence and eventually clear intracellular pathogens.
Regulation of Fe metabolism as a host disease tolerance mechanism
As discussed above, some immune-driven resistance mechanisms can encompass subtle alterations of host Fe metabolism characterized by a systemic reduction of circulating Fe levels, termed hypoferremia. This is compensated by the expansion of Fe stores within the reticuloendothelial system, termed hyperferritinemia [175, 176] . This dual effect contributes critically to host protection against infection by extracellular/circulating microbes, based on limiting Fe availability while regulating antimicrobial immunedriven resistance mechanisms. As a trade-off, however, immunedriven hypoferremia and hyperferritinemia can become pathologic. Sustained hypoferremia reduces Fe availability to erythropoiesis and can thus result in the development of anemia of chronic disease also known as anemia of inflammation [177] . This form of anemia is considered the second most frequent worldwide and is found in individuals suffering from infections or immune-mediated inflammatory diseases, such as cancer and systemic autoimmune disorders [177, 178] . Anemia of inflammation is associated with reduced cardiovascular performance along with tissue hypoxia and overall impaired quality of life [179] . These clinical outcomes evolve irrespective of the host's pathogen burden likely reflecting impaired disease tolerance [1] .
Anemia of inflammation, caused by extracellular pathogens, is driven by hepcidin-and cytokine-mediated reduction of Fe efflux from Mø as well as reduced Fe dietary absorption [113] . In contrast, intracellular pathogens like Mycobacteria or Salmonella trigger anemia of inflammation independent of hepcidin via a mechanism involving the induction of Lcn2 and NRAMP1 expression and enhanced FPN function in Mø [180, 181] . This suggests that in a similar manner to resistance mechanisms, regulatory mechanisms controlling host Fe metabolism modulate disease tolerance in a pathogen class-specific manner.
Irrespective of pathogen class, anemia of inflammation is associated with the development of tissue hypoxia and hence with the activation of hypoxia-inducible factor (HIF). This family of transcription factors regulates the expression of several erythropoietic factors and hormones, which stimulate erythropoiesis. Erythropoietin (Epo), the major erythropoiesis stimulatory hormone, regulates Fe metabolism via the induction of TfR expression and Fe uptake into erythroid progenitor cells [182] as well as via stimulation of erythroferrone, a hormone that inhibits hepcidin expression, thereby increasing Fe availability for erythropoiesis [183] . Several cytokines driving immune resistance mechanisms can reduce Epo expression, blunting this adaptive response [177, 184, 185] . In some cases, this may be beneficial, because Epo exerts immunoregulatory effects that impair resistance to bacterial infections [186] . Other hematopoiesis-derived factors, such as the growth differentiation factor 15 (GDF15), can also reduce hepcidin expression, but their relative importance in the setting of anemia of inflammation appears to be limited [65, 187] . Activation of HIFs can also inhibit hepcidin expression while inducing the expression of Fe transporters in the duodenum, thereby fostering Fe absorption from diet [188, 189] . Moreover, hypoxia-induced hormones, such as PDGF-BB, also inhibit hepcidin transcription [64] (Fig 3) . The interplay of all these factors with Fe homeostasis in the setting of anemia of inflammation and their impact on antimicrobial host immune responses during infection remains largely unknown.
Infection by extracellular pathogens can involve the development of tissue Fe overload, as observed for infectious diseases associated with more or less severe hemolysis. Accumulation of extracellular hemoglobin can exert pathogenic effects that foster the pathogenesis of infectious diseases, as illustrated for the development of severe sepsis in response to systemic polymicrobial infections in mice [190] . This is also the case for the development of severe forms of malaria in response to Plasmodium infection in mice [103] [104] [105] [106] 191, 192] . These often-lethal pathologic conditions can be dissociated from host pathogen burden, suggesting that extracellular hemoglobin impairs disease tolerance to sepsis and malaria. The clinical relevance of this pathologic process is strongly supported by the finding that accumulation of extracellular hemoglobin is associated with higher risk of death from severe sepsis [193, 194] . Moreover, reduced levels of the hemoglobin scavenger haptoglobin are also associated with increased malaria severity [195] .
The mechanisms underlying the pathogenic effects of extracellular hemoglobin were associated originally to NO scavenging, reducing NO bioavailability, and impairing microvascular homeostasis [192, 196] (Fig 4) . This was suggested to contribute to the pathogenesis of severe forms of malaria in mice, without interfering with host pathogen burden [192] , thus arguing that NO scavenging by extracellular hemoglobin impairs disease tolerance to Plasmodium infection. There are, however, other mechanisms contributing to the pathogenic effects of extracellular hemoglobin. When exposed to NO, the peroxidase activity of extracellular hemoglobin can catalyze the generation of cytotoxic peroxynitrate (ONNO À ) a highly toxic RNS fostering microvascular dysfunction.
To what extent this impairs disease tolerance to malaria and/or other infectious diseases is not clear given that ONNO À can induce the activation of the transcription factor Nrf2 and promote disease tolerance to malaria [191] . )hemoglobin [198] . Electron transfer from Fe 4+ can oxidize tyrosines in the globulin chains of hemoglobin, giving rise to dityrosine bonds that promote the generation of ferrylhemoglobin aggregates [198] . When deposited on the surface of vascular endothelial cells, these become vasoactive and pro-inflammatory [198] , presumably contributing to the pathogenesis of systemic infections associated with hemolysis and vasculitis. Extracellular methemoglobin can release its non-covalently bound heme [38, 104, 105, 190, [199] [200] [201] , generating labile heme, that is, redox active heme that is loosely bound to plasma proteins or to other molecules (Fig 4) . Labile heme plays a central role in the pathogenesis of severe forms of malaria as well as severe sepsis in mice [103, 105, 190] . The pathogenic effect of labile heme can be dissociated from the host's pathogen burden [103, 105, 190] , suggesting that labile heme impairs disease tolerance to these systemic infections. The clinical relevance of this pathologic process is strongly supported by the recent finding that heme accumulation in plasma is associated with the development of severe forms of malaria in humans [202] .
The mechanisms underlying the pathogenic effects of labile heme are probably diverse, but there is a growing body of evidence to suggest that labile heme acts as a pro-inflammatory agonist through the engagement of TLR-4 in Mø [203, 204] and endothelial cells [205] (Fig 4) . Free heme can also engage other PRR, as illustrated for NALP3 [206] . Given the central role played these PRR in the activation of innate immunity, labile heme is likely to tailor resistance to infections associated with more or less severe hemolysis. Labile heme also exerts chemotactic effects via the activation of G protein-coupled receptors expressed in PMN cells [207] , while promoting the release of neutrophil extracellular traps (NETs) from activated PMN cells [208] (Fig 4) .
Once released from hemoglobin, the redox activity of labile heme becomes pro-oxidant and cytotoxic [38, 106, 107, 190] (Fig 4) . Presumably, it is this cytotoxic effect that promotes tissue damage and hence compromises disease tolerance to malaria and severe sepsis [103, 105, 190] . Briefly, labile heme sensitizes parenchyma cells to undergo programmed cell death in response to proinflammatory cytokines such as TNF [106] as well as other agonists such as Fas as well as ROS and RNS [38, 190] . The mechanism underlying heme-mediated cytotoxicity involves the sustained activation of the c-Jun N-terminal kinase (JNK) signaling transduction pathway [107] (Fig 4) . Heme overrides the cytoprotective program set in motion by the transcription factor NF-jB [209] , which prevents sustained JNK activation and programmed cell death [210, 211] [216] . However, heme-driven programmed cell death is also suppressed by pharmacologic inhibition of the receptor-interacting serine/threonine kinases 1 (RIPK1), as well as by the deletion of the Ripk3 gene (unpublished observation). This suggests that heme might also trigger necroptosis [217] . This is in line with the finding that sustained JNK activation shifts TNF-mediated programmed cell death from apoptosis to necrosis [217, 218] and that heme can trigger necroptosis in Mø, via an autocrine loop in which heme triggers the production of TNF upon the engagement of TLR4 [173] .
The pathogenic effects exerted by extracellular hemoglobin and labile heme are countered by adaptive responses that converge at the level of heme catabolism by HO-1 [38,219], providing tissue damage control and disease tolerance to systemic infections [103,105,106] (Fig 4) . The emergence of several stress-responsive genetic programs culminating in the catabolism of labile heme is probably required to neutralize its pro-inflammatory [203, 204, 207] , vasoactive [205] , and cytotoxic [38,104-106] effects [219] (Fig 4) . When coupled to other mechanisms regulating Fe homeostasis, HO-1 avoids tissue Fe overload and tissue damage while sustaining Fe supply to erythropoiesis to maintain Fe homeostasis during infection [38,54,219,220] (Fig 4) . This notion is strongly supported . Cytotoxic products generated by pathogens can damage RBC, which are rapidly engulfed and cleared by Mø. Alternatively, damaged RBC release hemoglobin (HB) into plasma, which can exert deleterious effects, compromising disease tolerance. For example, extracellular hemoglobin can scavenge NO, promoting vasoconstriction and eventually affecting microvascular circulation (top). Oxidized extracellular hemoglobin can also release heme, which acts as a pro-inflammatory agonist in endothelial cells and Mø via TLR4, or via GPCRs in PMN cells. Labile heme sensitizes parenchyma cells to undergo programmed cell death in response to TNF, leading to tissue damage and compromising disease tolerance (right). These pathogenic effects are countered by tissue damage control mechanisms that confer disease tolerance to infection. The hemoglobin and heme scavengers HP and HPX, respectively, shuttle heme for degradation by HO-1 via the Mø scavenger receptors CD163 and CD91 (middle). This is coupled to mechanisms regulating intracellular Fe reactivity. These include ferritin, which stores intracellular Fe and FPN, which delivers Fe to Tf and supports erythropoiesis. This prevents anemia and tissue hypoxia, an effect likely to promote disease tolerance. This heme/Fe detoxifying mechanism also operates in parenchyma tissues to prevent programmed cell death and tissue damage, presumably enforcing disease tolerance (right). One of the mechanisms relies on the Fe-scavenging capacity of ferritin, which acts in an antioxidant manner and prevents sustained JNK activation from triggering programmed cell death in response to TNF. Moreover, HO-1 enzymatic activity generates CO, which promotes the secretion of IL-10 in activated Mø, impacting on MHC class II/TCR-driven activation of T H cells and thereby contributing to tissue damage control and eventually to disease tolerance (middle). CO also binds to the heme groups of extracellular hemoglobin and prevents heme release, thus protecting tissues from the vasoactive, pro-inflammatory, and cytotoxic effects of labile heme. Finally, CO is a potent cytoprotective molecule that prevents tissue damage and as such can enforce disease tolerance to infection. [173, 224] . Whether these effects are exerted when HO-1 is expressed by Mø and/or in parenchyma cells is not clear (Fig 4) . In the context of systemic infections, the protective effects exerted by HO-1 are assisted by FTH [54,107] (Fig 4) [227] . Moreover, CO acts per se as a cytoprotective molecule [172, 228] , which should also contribute to promote tissue damage control and disease tolerance to malaria. The finding that sickle hemizygous mutations confer protection against malaria via a CO-dependent mechanism supports its pathophysiological relevance [103] [104] [105] . Namely, sickle hemoglobin mutations induce the generation of labile heme, which triggers the activation of the transcription factor Nrf2 and the expression of HO-1 [103, 104] . Production of CO by HO-1 targets the extracellular hemoglobin generated during the blood stage of Plasmodium infection and prevents the pathogenesis of severe forms of malaria [103] [104] [105] . This protective effect is not associated with modulation of host pathogen load, revealing that sickle hemoglobin mutations confer disease tolerance to malaria [103, 104] . It is likely that a similar mechanism underlies the protective effect exerted by other chronic hemolytic conditions against malaria, including hemoglobin C [229, 230] , glucose 6 phosphate dihydrogenase (G6PD) deficiency in males [231] , b-or a-thalassemia [230] as well as mutations involved in RBC cytoskeleton or membrane protein defects [232] .
Targeting Fe/heme metabolism in the treatment of infectious diseases
There is an urgent need of alternative treatment strategies that can cope with the recent raise of microbial resistance to antimicrobial [234] . Delivery of Lcn2 by probiotic bacteria has also been shown to control Salmonella infection [235] . Systemic Fe chelation by desferrioxamine can improve the clinical course of malaria, without, however, providing an overt survival benefit [236] . In mucormycosis, an invasive mold infection, desferrioxamine shows adverse outcomes because mucorales can use desferrioxamine as a Fe source [237] . However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238] . However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28] . Finally, approaches which block microbial Fe acquisition pathways, including binding of host Fe proteins, may prove to be effective in limiting microbial proliferation and pathogenicity as shown for Aspergillus spp. [33] . Pharmacologic targeting of heme metabolism may also be used to modulate host resistance and/or tolerance to intracellular and extracellular infections. Perhaps the strongest argument in support of this strategy is provided by anti-malarial drugs, which target in most cases Plasmodium heme metabolism [239] . Pharmacologic induction of HO-1 has also been used experimentally to modulate resistance or tolerance to bacterial or protozoan infections in mice [220] . Another possible venue for intervention is to target heme release from extracellular hemoglobin, such as afforded by pharmacologic administration of CO, which may be used clinically [240] to confer disease tolerance to malaria [103] [104] [105] . The recent finding that HO-1 is central to support resistance to Mycobacteria infection in mice suggests that targeting heme catabolism may be used therapeutically against tuberculosis [170] . Whether pharmacologic use of hemoglobin or heme scavengers, such as haptoglobin or HPX, may be used therapeutically to avoid the deleterious effects of extracellular hemoglobin and labile heme, respectively, remains to be established. It is likely as well that interfering with heme cellular trafficking in pathogenic microbes or in the infected host may have therapeutic value. 
Concluding remarks
The ever-evolving nature of host-microbe interaction relies on the establishment and continuous adjustment of an intricate network of mechanisms controlling the availability of essential metabolites and nutrients. Perhaps the best studied of these is Fe, a central and vital nutrient required for host as well as microbial survival. This relationship is complex and pathogen class-specific strategies evolved to control Fe and heme availability to intracellular versus extracellular pathogens. Pathogen virulence often emerges via natural selection of genes that favor Fe and/or heme uptake by microbes, suggesting that targeting such mechanisms may be of therapeutic value to combat infectious diseases. 
